Literature DB >> 30900183

Fragile X Syndrome Pre-Clinical Research: Comparing Mouse- and Human-Based Models.

Michael Telias1.   

Abstract

Despite almost 30 years of biomedical research, a treatment or cure for fragile X syndrome (FXS) is not yet available. The reasons behind this are varied, and among them are discrepancies in both research methodologies and research models. For many years, the fmr1 knockout mouse model dominated the field, and was used to draw important conclusions. The establishment of FXS-human cellular models called these conclusions into question, showing conflicting evidence. Discrepancies in FXS research, between mouse and human, might arise from differences inherent to each species, and from the use of different methodologies. This chapter summarizes these discrepancies and evaluates their impact on the current status of clinical trials.

Entities:  

Keywords:  Clinical trials; Clinical trials in FXS; FXS cure; FXS pharmacology; FXS treatment; Neurodevelopmental disorders; Treatment of neurodevelopmental disorders

Mesh:

Substances:

Year:  2019        PMID: 30900183     DOI: 10.1007/978-1-4939-9080-1_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  1 in total

1.  OTC intron 4 variations mediate pathogenic splicing patterns caused by the c.386G>A mutation in humans and spfash mice, and govern susceptibility to RNA-based therapies.

Authors:  Claudia Sacchetto; Laura Peretto; Mirko Pinotti; Dario Balestra; Francisco Baralle; Iva Maestri; Francesca Tassi; Francesco Bernardi; Stan F J van de Graaf; Franco Pagani
Journal:  Mol Med       Date:  2021-12-14       Impact factor: 6.354

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.